US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00%
FinancialContent

OS Therapies Incorporated Common Stock (NY:OSTX)

1.620 UNCHANGED
Delayed Quote Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OS Therapies Incorporated Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
From OS Therapies, Inc.
Via Business Wire
News headline image
OS Therapies Announces Pricing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
News headline image
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
From OS Therapies, Inc.
Via Business Wire
News headline image
OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024 ↗
OS Therapies just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
OS Therapies Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
OS Therapies to Present at The Spartan Capital Investor Conference
From OS Therapies
Via Business Wire
News headline image
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
From OS Therapies
Via Business Wire
News headline image
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
From OS Therapies
Via Business Wire
News headline image
OS Therapies to Present at the LD Micro Main Event XVII
From OS Therapies
Via Business Wire
News headline image
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From OS Therapies
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
From OS Therapies
Via Business Wire
News headline image
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
From OS Therapies
Via Business Wire
News headline image
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector 
Via News Direct
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (OSTX, ATNM, CRBP, PBYI)
Via AB Newswire
News headline image
Transforming Oncology: Stocks to Watch in the Oncology Sector
Transforming Oncology: Stocks to Watch in the Oncology Sector 
Via News Direct
News headline image
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Via ACCESSWIRE
News headline image
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
From OS Therapies
Via Business Wire
News headline image
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
From OS Therapies
Via Business Wire
News headline image
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
From OS Therapies
Via Business Wire
News headline image
OS Therapies Clarifies CUSIP of Common Stock
From OS Therapies
Via Business Wire
News headline image
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
From OS Therapies
Via Business Wire
News headline image
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board
Via ACCESSWIRE
News headline image
OS Therapies Falls Following Downsized IPO ↗
Shares of OS Therapies fell on Thursday following a downsized initial public offering by the oncology drug developer in a slow week for the IPO market. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Dow Dips Over 400 Points; Apple Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board
From OS Therapies Incorporated
Via Business Wire
News headline image
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >